Cancer drug combo tested for rare gene mutation – but trial stopped early
NCT ID NCT05523440
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested two drugs, niraparib and bevacizumab, alone or together, in people with recurrent endometrial or ovarian cancer that has a specific gene change called ARID1A. The goal was to see if the drugs could shrink tumors. However, the trial was stopped early after enrolling only 9 participants, so the findings are very limited.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
niraparib (Zejula) and bevacizumab (Avastin)
What this could lead to
If successful, this could point toward a targeted treatment option for people with recurrent endometrial or ovarian cancer that has an ARID1A mutation.
What could go wrong
The trial was terminated early with only 9 participants, so results are very limited and may not be reliable. It is also a Phase 2 study, meaning it is still early and may not lead to a standard treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT OVARIAN CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Oklahoma Health Sciences Center, Stephenson Cancer Center
Oklahoma City, Oklahoma, 73104, United States
-
University of Virginia Comprehensive Cancer Center
Charlottesville, Virginia, 22903, United States